Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice

Area of Science:

• Cardiovascular Research
• Nanomedicine
• Oxidative Stress Biology

Background:

• Ischemia/reperfusion (I/R) injury leads to significant myocardial damage due to reactive oxygen species (ROS) and subsequent inflammation and apoptosis.
• Bilirubin is a potent endogenous antioxidant with ROS-scavenging capabilities.
• Previously developed bilirubin nanoparticles (BRNPs) offer a potential therapeutic strategy.

Purpose of the Study:

• To investigate the therapeutic efficacy of bilirubin nanoparticles (BRNPs) in mitigating myocardial ischemia/reperfusion (I/R) injury in a mouse model.
• To assess the impact of BRNPs on cardiac function, infarct size, oxidative stress, inflammation, and apoptosis following I/R injury.

Main Methods:

• Cardiac I/R injury was induced in mice by ligating and then releasing the left anterior descending coronary artery.
• Bilirubin nanoparticles (BRNPs) were administered intraperitoneally before and after reperfusion.
• Cardiac function was evaluated using echocardiography and pressure-volume loop measurements.
• In vivo imaging tracked BRNP distribution, demonstrating preferential targeting to the injured heart site.

Main Results:

• BRNP treatment significantly improved cardiac output and overall cardiac function compared to vehicle control.
• A significant reduction in myocardial infarct size was observed in mice treated with BRNPs.
• BRNPs effectively suppressed reactive oxygen species (ROS) and pro-inflammatory factor levels.
• BRNP administration markedly decreased cardiac apoptosis.

Conclusions:

• Bilirubin nanoparticles (BRNPs) demonstrate significant therapeutic potential for myocardial I/R injury.
• BRNPs exert protective effects by attenuating oxidative stress, inflammation, and apoptosis.
• BRNPs represent a promising novel therapeutic modality for managing cardiac I/R injury.